Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fluoguide A/S has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The company's current patent prosecution is highly focused on this single pharmaceutical matter. With only 1 pending office action, the company can concentrate its legal and technical resources on resolving the specific objections raised in this application.
XIE, XIAOZHEN is the busiest examiner for the portfolio, managing 1 busiest examiner pending action. This examiner is responsible for the only active office action currently on record. Practitioners must engage directly with this examiner to navigate the specific hurdles presented in this single pending case. Because the prosecution is limited to 1 distinct examiner and 1 distinct art unit, the company has a clear and direct path to potential allowance, provided it can satisfy the specific requirements and technical standards of the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XIE, XIAOZHEN | 1 | 56.6% | +65.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18272210 | A UPAR (UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR)-TARGETING CONJUGATE | XIE, XIAOZHEN | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18272210 | A UPAR (UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR)-TARGETING CONJUGATE | XIE, XIAOZHEN | 1674 | §102§112DP | Non-Final OA | — | Pending | Jul 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial